Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination oral pharmaceutical product containing **aspirin**, **magnesium hydroxide**, and **aluminum hydroxide** is used primarily to provide the anti-inflammatory, analgesic, and antipyretic effects of aspirin while minimizing gastrointestinal irritation through buffered antacid components. **Aspirin** inhibits cyclooxygenase enzymes, reducing the synthesis of prostaglandins involved in pain, fever, and inflammation, and irreversibly inhibits platelet aggregation. **Magnesium hydroxide** and **aluminum hydroxide** act as antacids, neutralizing gastric acid and protecting the gastric mucosa. This combination is intended to reduce the gastrointestinal side effects associated with aspirin therapy[8][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + magnesium hydroxide + aluminum hydroxide.